|
KMID : 0390320120220020103
|
|
Chungbuk Medical Journal
2012 Volume.22 No. 2 p.103 ~ p.109
|
|
|
The Effects of Providing Information about the Side Effects before Using Anticholinergic Agents in the Patient with Overactive Bladder Symptom : a Prospective, Single-Center, Observational Study
|
|
Kim Sung-Min
Kang Ho-Won
Kim Won-Tae
Kim Yong-June
Yun Seok-Joong
Lee Sang-Cheol
Kim Wun-Jae
|
|
|
Abstract
|
|
|
Purpose: Anticholinergic agents can be used as primary treatment in patients with overactive bladder (OAB) symptom. But drug side effects can make the doctor hesitating in using anticholinergic agents and can influence on drug compliance of the patients. The aim of this study is to examine the effects of providing information about the side effects of anticholinergic agents before using.
Materials and Methods: Data were collected on patients who visited Chungbuk National University Hospital between March 2011 and June 2011. And 60 female patients with 3 or more overactive bladder symptom score (OAB-SS) were enrolled. Patients with narrow-angled glaucoma, gastrointestinal stasis, history of urinary retention were excluded. All the patients were administrated 5 mg of solifenacin succinate. 30 patients were provided information about the side effects of anticholinergic agents (Group I), and other 30 patients were provided no drug information. Before treatment with solifenacin (V1), 1 (V2), 3 (V3) and 12 (V4) months after starting solifenacin, OAB-SS were measured. The side effects were checked at each visit.
Results: There was no difference in age, body mass index (BMI) and duration of symptom. Also, no difference in functional bladder capacity, daytime frequency, and nocturnal frequency on 3-days voiding diary before administration. After treatment, reduction of OAB-SS was 3.61±2.61 in group I and 3.42±2.57 in group II, and occurrence of significant side effects was 2 events in group I and 4 events in group II (each p>0.05). But occurrence of remnant medication was more frequent in group I than group II, and mean follow-up period was longer in group II than group I with
significant between group-differences (3 vs. 1; 5.53±4.52 months vs. 7.97±4.63 months, each p=0.04).
Conclusion: Providing information about the side effects of anticholinergic agents before using had no influence on reduction of OAB-SS and occurrence of side effects. But it made patients leave more remnant pills, and it reduced mean follow-up period. Therefore, additional information need to be given to the patients with OAB in order to improve drug compliance, when the clinicians explain the side effects of anticholinergic agents.
|
|
|
KEYWORD
|
|
|
Anticholinergic agents, Side effect, Education, Drug compliance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|